Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Wish you could know what management really thought about their companies?

One great way for an inside look is to consider the stock buying trends of company insiders. Companies with significant net buying from their insiders (i.e. members of the board and upper management) are viewed favorably by analysts because the buying indicates that insiders who know more about their companies than anybody are bullish about their employers.

We ran a screen on the healthcare sector for stocks seeing the most significant net insider buying over the last six months.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these stocks will outperform like insiders expect? Use this list as a starting point for your own analysis.

List sorted by net insider purchases as a percent of sharefloat.

1. Theravance Inc. (NASDAQ:THRX): Engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system /pain. Market cap of $1.67B. Net insider shares purchased over the last six months at 5.19M, which is 9.99% of the company's 51.96M share float. The stock is a short squeeze candidate, with a short float at 10.04% (equivalent to 19.12 days of average volume). It's been a rough couple of days for the stock, losing 11.8% over the last week.

2. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG): Engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Market cap of $396.44M. Net insider shares purchased over the last six months at 991.15K, which is 7.36% of the company's 13.46M share float. The stock is a short squeeze candidate, with a short float at 6.92% (equivalent to 6. days of average volume). The stock has gained 5.71% over the last year.

3. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): Engages in the development and commercialization of novel therapeutics to treat severe lipid disorders. Market cap of $325.99M. Net insider shares purchased over the last six months at 695.15K, which is 6.14% of the company's 11.32M share float. It's been a rough couple of days for the stock, losing 5.52% over the last week.

4. Opko Health, Inc. (NYSE:OPK): Engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. Market cap of $1.38B. Net insider shares purchased over the last six months at 6.85M, which is 5.19% of the company's 132.02M share float. The stock has gained 22.94% over the last year.

5. MannKind Corp. (NASDAQ:MNKD): Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Market cap of $309.96M. Net insider shares purchased over the last six months at 3.48M, which is 4.69% of the company's 74.22M share float. The stock is a short squeeze candidate, with a short float at 34.64% (equivalent to 40.98 days of average volume). It's been a rough couple of days for the stock, losing 10.27% over the last week.

6. Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL): Operates as a specialty biopharmaceutical company primarily in the United States. Market cap of $934.78M. Net insider shares purchased over the last six months at 973.07K, which is 2.20% of the company's 44.15M share float. The stock is a short squeeze candidate, with a short float at 10.27% (equivalent to 6.98 days of average volume). The stock has had a good month, gaining 10.97%.

7. Ardea Biosciences, Inc. (NASDAQ:RDEA): Focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Market cap of $432.18M. Net insider shares purchased over the last six months at 495.55K, which is 2.16% of the company's 22.96M share float. The stock is a short squeeze candidate, with a short float at 7.87% (equivalent to 18.88 days of average volume). The stock has performed poorly over the last month, losing 19.27%.

8. Genomic Health Inc. (NASDAQ:GHDX): Focuses on the development and global commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Market cap of $756.22M. Net insider shares purchased over the last six months at 554.75K, which is 2.06% of the company's 26.92M share float. The stock is a short squeeze candidate, with a short float at 6.96% (equivalent to 10.9 days of average volume). The stock has gained 15.94% over the last year.

9. MAKO Surgical Corp. (NASDAQ:MAKO): A medical device company, markets its advanced robotic arm solution and orthopedic implants for orthopedic procedures in the United States and internationally. Market cap of $1.17B. Net insider shares purchased over the last six months at 485.14K, which is 1.32% of the company's 36.64M share float. The stock is a short squeeze candidate, with a short float at 27.28% (equivalent to 10.74 days of average volume). The stock has had a couple of great days, gaining 6.98% over the last week.

10. Seattle Genetics Inc. (NASDAQ:SGEN): Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Market cap of $1.90B. Net insider shares purchased over the last six months at 1.48M, which is 1.30% of the company's 113.40M share float. The stock is a short squeeze candidate, with a short float at 22.38% (equivalent to 13.56 days of average volume). The stock has gained 7.5% over the last year.

11. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. Market cap of $5.35B. Net insider shares purchased over the last six months at 675.38K, which is 0.95% of the company's 70.75M share float. The stock is a short squeeze candidate, with a short float at 12.88% (equivalent to 7.11 days of average volume). The stock has gained 73.87% over the last year.

12. QLT Inc. (NASDAQ:QLTI): Engages in the development and commercialization of therapies for the eye. Market cap of $354.79M. Net insider shares purchased over the last six months at 258.32K, which is 0.88% of the company's 29.40M share float. The stock has lost 8.26% over the last year.

13. Medivation, Inc. (NASDAQ:MDVN): Focuses on the development of small molecule drugs for the treatment of castration-resistant prostate cancer, Alzheimer's disease, and Huntington disease. Market cap of $1.60B. Net insider shares purchased over the last six months at 87.52K, which is 0.38% of the company's 23.14M share float. The stock has gained 180.54% over the last year.

14. Questcor Pharmaceuticals, Inc. (QCOR): Provides prescription drugs for central nervous system and inflammatory disorders. Market cap of $2.48B. Net insider shares purchased over the last six months at 181.88K, which is 0.33% of the company's 55.74M share float. The stock is a short squeeze candidate, with a short float at 11.71% (equivalent to 6.09 days of average volume). The stock has gained 175.02% over the last year.

15. Idenix Pharmaceuticals Inc. (NASDAQ:IDIX): Engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. Market cap of $744.13M. Net insider shares purchased over the last six months at 38.08K, which is 0.06% of the company's 63.49M share float. The stock is a short squeeze candidate, with a short float at 8.37% (equivalent to 6.67 days of average volume). It's been a rough couple of days for the stock, losing 7.24% over the last week.

16. Akorn, Inc. (NASDAQ:AKRX): Engages in the manufacture and marketing of diagnostic and therapeutic pharmaceutical products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. Market cap of $1.04B. Net insider shares purchased over the last six months at 33.50K, which is 0.05% of the company's 67.75M share float. The stock has gained 94.87% over the last year.

*Insider data sourced from Yahoo! Finance, all other data sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Source: 16 Healthcare Stocks Insiders Want Most